Factor XIII replacement in stem cell transplant (SCT) recipients with severe graft-versus-host disease of the bowel: report of an initial experience.
BACKGROUND
Severe acute graft-versus-host disease (aGVHD) of the gut is a serious and frequent posttransplantation event associated with a high mortality rate. We report on our experience with factor XIII replacement in patients with severe aGVHD of the bowel after allogeneic hematopoietic stem cell transplantation.


METHODS
Twenty-seven patients after allogeneic stem cell transplantation and severe aGVHD of the gut were enrolled. All patients suffered from bloody diarrhea that required packed red blood cell infusions. All patients received high-dose immunosuppression in combination with coagulation factor XIII (5,000 units initially, followed by 20 IU/kg body weight three times a day) for up to 3 weeks.


RESULTS
After 8 days of factor XIII replacement and unchanged high-dose immunosuppression, we observed a significant reduction in the red blood cell requirement of 21 patients.


CONCLUSIONS
We conclude that factor XIII replacement might be a useful supplementation in the treatment of aGVHD of the bowel.
Grothaus-Pinke
B
B
Department of Hematology/Oncology, Dr. Ottmar-Kohler Str. 2, D-55743 Idar-Oberstein, Germany.
Günzelmann
S
S
Fauser
A A
AA
Kiehl
M G
MG
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D005176:Factor XIII / Q000627:therapeutic use*; D005260:Female; D006086:Graft vs Host Disease / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006801:Humans; D007410:Intestinal Diseases / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D014184:Transplantation, Homologous
D005176:Factor XIII